Contrasting Gerresheimer (OTCMKTS:GRRMF) and AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) and Gerresheimer (OTCMKTS:GRRMF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings for AngioDynamics and Gerresheimer, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	0	0	4	0	3.00
Gerresheimer	0	0	1	0	3.00

AngioDynamics presently has a consensus target price of $12.25, suggesting a potential upside of 57.46%. Given AngioDynamics’ higher probable upside, equities research analysts clearly believe AngioDynamics is more favorable than Gerresheimer.

Institutional and Insider Ownership

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 53.2% of Gerresheimer shares are owned by institutional investors. 5.1% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares AngioDynamics and Gerresheimer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-61.55%	-4.91%	-3.76%
Gerresheimer	N/A	N/A	N/A

Earnings & Valuation

This table compares AngioDynamics and Gerresheimer”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$303.91 million	1.03	-$184.35 million	($4.84)	-1.61
Gerresheimer	N/A	N/A	N/A	$2.27	45.86

Gerresheimer has lower revenue, but higher earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Gerresheimer, indicating that it is currently the more affordable of the two stocks.

About AngioDynamics

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

About Gerresheimer

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services. It also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, the company offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. It offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.